Sun Pharma to Acquire Organon in $11.75 Billion Strategic Expansion

Sun Pharmaceutical Industries has entered into a definitive agreement to acquire New Jersey-based Organon & Co for $11.75 billion, including debt. Under the terms of the all-cash transaction, Sun Pharma will acquire all outstanding shares of Organon for $14 per share. Organon, which was spun off from Merck in 2021, maintains a diverse portfolio of over 70 products specializing in biosimilars and women's health, with operations spanning 140 countries. The acquisition is a strategic move by Sun Pharma to scale its presence in the United States, a critical market for the company's growth. A primary driver of the deal is the expansion of Sun Pharma's 'Innovative Medicines' business. Currently, this segment accounts for 20% of the company's total sales; following the integration of Organon, this contribution is expected to rise to 27% of the topline. The transaction is expected to elevate Sun Pharma into the top 25 global pharmaceutical companies, with revenues reaching $12.4 billion. Market reaction was mixed upon the announcement; Organon shares rose nearly 31% following initial reports of the deal, while Sun Pharma's stock closed 3.6% lower as investors processed the scale of the acquisition.